• Home
  • About CML
    • Who We Are
    • What we Do
    • Mission & Vision
    • The Patient Advisory Board
  • What is CML
  • Treatments
    • Access
    • Living Well
    • Clinical Trials
  • News
  • Contact
  • Home
  • About CML
    • Who We Are
    • What we Do
    • Mission & Vision
    • The Patient Advisory Board
  • What is CML
  • Treatments
    • Access
    • Living Well
    • Clinical Trials
  • News
  • Contact

Bosulif Conditionally Approved in Canada – Approuve Conditionnellement

•22 October 2024

Health Canada CONDITIONALLY approves BOSULIF – a new medication for chronic myelogenous leukemia
Approval provides new treatment option for Canadians suffering from rare cancer

SANTÉ CANADA APPROUVE CONDITIONNELLEMENT L’EMPLOI DE BOSULIF – UN NOUVEAU MÉDICAMENT CONTRE LA LEUCÉMIE MYÉLOÏDE CHRONIQUE
Les Canadiens bénéficient ainsi d’une nouvelle option de traitement pour un cancer rare 

Previous PostCanadian CML Patients being treated with iClusig (Ponatinib)Next PostBosulif (™) (bosutinib)

Related Posts

ACCESS TO AFFORDABLE MEDICINE FOR ALL

CML Access to Medicine

APO-IMATINIB

Apo – imatinib – Treatment for CML



CML Society of Canada provides support, education and information on CML, current and emerging treatments and research initiatives for people living with CML and their families.

Contact Centre

1 (514) 239-5488

All Across Canada

Mon – Fri: 8.00am 6.00pm

Member Resources

  • About CML
  • What is CML
  • Contact Us
  • Treatments
  • News
  • Videos

Our Newsletter

Copyright ©2024 CML. All Rights Reserved. Legal and Privacy.